Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 5:13 pm Sale |
2024-05-21 | 13G | Erasca, Inc. ERAS |
ARCH Venture Fund X L.P. | 0 0.000% |
-11,055,554 (Position Closed) |
Filing History |
| 2023-11-17 4:23 pm Sale |
2023-11-08 | 13G | EQRx, Inc. EQRX |
ARCH Venture Fund X L.P. | 0 0.000% |
-36,335,375 (Position Closed) |
Filing History |
| 2023-02-13 4:08 pm Sale |
2022-12-31 | 13G | Verve Therapeutics, Inc. VERV |
ARCH Venture Fund X L.P. | 0 0.000% |
-2,508,809 (Position Closed) |
Filing History |
| 2023-02-13 4:08 pm Purchase |
2022-12-31 | 13G | Prime Medicine, Inc. PRME |
ARCH Venture Fund X L.P. | 12,272,674 12.600% |
12,272,674 (New Position) |
Filing History |
| 2022-02-11 4:57 pm Purchase |
2021-12-31 | 13G | EQRx, Inc. EQRX |
ARCH Venture Fund X L.P. | 36,335,375 7.500% |
36,335,375 (New Position) |
Filing History |
| 2022-02-10 5:04 pm Purchase |
2021-12-31 | 13G | Erasca, Inc. ERAS |
ARCH Venture Fund X L.P. | 11,055,554 9.100% |
11,055,554 (New Position) |
Filing History |
| 2022-02-09 1:26 pm Purchase |
2021-12-31 | 13G | Verve Therapeutics, Inc. VERV |
ARCH Venture Fund X L.P. | 2,508,809 5.200% |
2,508,809 (New Position) |
Filing History |